Skip to main content

Market Overview

Cerus, FDA Reach Agreement on Modular Premarket Approval Application Submission Process for INTERCEPT Plasma

Share:

Cerus Corporation (NASDAQ: CERS) announced today that the U.S. Food and Drug Administration (FDA) has accepted its proposed modular Premarket Approval application (PMA) shell for review of the INTERCEPT Blood System for plasma. A PMA shell is an outline of the application process that defines the structure, content and timing of each module. FDA and the applicant need to agree on a shell prior to initiation of a modular PMA submission.

A modular PMA review process is based on submission of a compilation of sections or "modules" at 90-day intervals that together become a complete PMA. Under a modular approach, FDA is able to review each module separately, allowing the applicant to receive timely feedback and potentially resolve deficiencies earlier in the review process than would be expected with a traditional PMA application.

Cerus recently announced its intention to pursue a modular PMA submission after dialogue with the FDA indicated that the company could proceed with an application for multiple indications of plasma use, not just the thrombotic thrombocytopenic purpura (TTP) indication for which Cerus received orphan drug designation last year.

 

Related Articles (CERS)

View Comments and Join the Discussion!

Posted-In: News FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com